Located in Rancho Cordova, California, Cesca Therapeutics specializes in the research, development, and commercialization of autologous cell-based therapeutics for regenerative medicine applications. With the stem cell and cord blood marketplace, the company is best known for it automated blood and bone marrow processing systems, such as the AutoXpress® Platform (AXP®), the MarrowXpress® Platform, the BioArchive® System, and others.
Already a dominant player with the cord blood banking markets, Cesca Therapeutics continues its dominance with today’s announcement that the Texas Stem Cell has entered into an agreement to use Cesca’s AutoXpress technology.
Located in Houston, Texas Stem Cell is a stem cell bank that offer the storage of newborn umbilical cord blood, cord tissue, and placenta. As a “hybrid” bank, it offers both private (fee-based) storage and public (free) donation of stem cell samples.
In news released today, the companies announced:
“Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that Texas Stem Cell has committed to utilizing Cesca’s AutoXpress® AXP technology for its cord blood banking business. The AXP platform includes a ‘smart’ processing device and sterile disposable that automatically concentrates the stem cells from a cord blood unit in less than one hour and delivers them directly into Cesca’s patented sample bag which is optimized for cryopreservation and storage.
Cesca’s AXP technology is widely used in cord blood banks around the world and has been referenced in dozens of clinical publications. Recently, clinical focus on cord blood has expanded due to the emergence of protocols enabling the expansion of cord blood cells in vitro, for subsequent therapeutic use in treatments for many forms of blood cancers including leukemia and lymphomas.”
To learn more about the agreement, see the company press release from Cesca Therapeutics.
As the first and only market research firm to specialize in the stem cell industry, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.